Clinical Report: One-Sided Diffuse Alveolar Hemorrhage in GPA

Background

Granulomatosis with polyangiitis (GPA) is a form of ANCA-associated vasculitis that can lead to serious pulmonary complications, including diffuse alveolar hemorrhage (DAH). Recent guidelines highlight the need for careful evaluation of pulmonary infiltrates in patients with GPA.

Data Highlights

This article does not contain numerical or trial data.

Key Findings

• Correction of the first author's name from Juan Molina Collada to Juan Molina-Collada.
• Granulomatosis with polyangiitis can present with unilateral diffuse alveolar hemorrhage.
• Bronchoalveolar lavage is recommended for evaluating pulmonary infiltrates in GPA.
• High-dose glucocorticoids combined with rituximab or cyclophosphamide are standard induction therapies for severe GPA.
• Routine use of adjunctive plasma exchange for alveolar hemorrhage is not recommended.

Clinical Implications

Understanding the management guidelines for GPA is essential.

Conclusion

Accurate authorship and adherence to clinical guidelines are vital in the management of granulomatosis with polyangiitis and its complications.

Related Resources & Content

1. Juan Molina-Collada, Clinical Rheumatology, 2019 -- Amendment: One-Sided Diffuse Alveolar Hemorrhage Associated with Granulomatosis with Polyangiitis
2. MDSpire News — Gingival Swelling and Recurrent Epistaxis: What’s Your Diagnosis?
3. ACR Open Rheumatology — Clinical Images: Characteristics of IgG4-Related Disease in a Patient Diagnosed with Granulomatosis with Polyangiitis
4. Clinical Rheumatology — Recurrent Subarachnoid Hemorrhage as a Clinical Presentation in Microscopic Polyangiitis: A Case Study and Review of Existing Literature
5. Frontiers in Medicine — Generalized Granuloma Annulare Associated with Lung Adenocarcinoma: A Case Report
6. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
7. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update - ScienceDirect
8. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis - PMC